VIGRANDE 100 mg (Sildenafil) is a pharmaceutical-grade oral phosphodiesterase type 5 (PDE5) inhibitor formulated as film-coated tablets, supplied in boxes of 4 tablets at 100 mg per tablet. Sildenafil is the original and most extensively researched compound in the PDE5 inhibitor drug class, with a clinical research history spanning decades across urology, cardiovascular medicine, and pulmonary pharmacology literature. Originally investigated as a cardiovascular agent for hypertension and angina management, sildenafil's selective inhibitory effects on PDE5 in penile vasculature were identified in clinical research and subsequently established its primary indication in erectile dysfunction pharmacotherapy.
 
✔ Key Research Insights
Studied for its role in inhibiting phosphodiesterase type 5 enzyme activity in penile corpus cavernosum smooth muscle, with documented enhancement of cGMP-mediated vasodilation and associated improvement in erectile function parameters in research subjects with erectile dysfunction
Investigated for its original cardiovascular research applications in systemic hypertension and angina, with its selective PDE5 inhibitory profile and vasodilatory mechanism documented across early-phase cardiovascular pharmacology trials
Researched for its clinical efficacy in erectile dysfunction across extensively documented subject populations, with established efficacy superiority over placebo referenced across international urology clinical guidelines
Examined for its pulmonary arterial vasodilatory effects via PDE5 inhibition in pulmonary vascular smooth muscle, representing a clinically distinct and well-established research and treatment application documented in cardiovascular and pulmonary medicine literature under the sildenafil designation
Documented for its pharmacokinetic profile, with an onset of action of approximately 30–60 minutes and duration of effect of 4–6 hours referenced in comparative PDE5 inhibitor research literature
Referenced across international clinical guidelines as a first-line pharmacological intervention for erectile dysfunction management
 
📦 Product Specifications
Product: VIGRANDE
Also Known As: Sildenafil (Viagra active ingredient)
Molecule: Sildenafil
Drug Class: Phosphodiesterase Type 5 (PDE5) Inhibitor
Concentration: 100 mg per tablet
Form: Film-coated oral tablet
Volume: 4 tablets per box
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Sildenafil is a selective inhibitor of the phosphodiesterase type 5 (PDE5) enzyme, the primary enzyme responsible for degradation of cyclic guanosine monophosphate (cGMP) in smooth muscle tissue of the corpus cavernosum and pulmonary vasculature. In research subjects experiencing erectile dysfunction, sexual stimulation triggers nitric oxide (NO) release from penile endothelial and neuronal cells, activating guanylate cyclase and elevating intracellular cGMP concentrations in corpus cavernosum smooth muscle. Sildenafil inhibits PDE5-mediated cGMP degradation, prolonging and amplifying the cGMP-mediated smooth muscle relaxation cascade, facilitating increased arterial inflow into cavernosal tissue and supporting erectile function parameters. As with all PDE5 inhibitors, sexual stimulation is a prerequisite for sildenafil's erectile effects — the compound amplifies the physiological NO-cGMP response to stimulation rather than initiating erection independently. Sildenafil's pharmacokinetic profile in research subjects is characterized by an onset of action of approximately 30–60 minutes following oral administration and a total duration of effect of approximately 4–6 hours, distinguishing it from the longer-acting tadalafil in comparative PDE5 inhibitor research. Of pharmacological note, sildenafil was originally developed as a cardiovascular vasodilator for systemic hypertension and angina management, with its selective PDE5 activity in penile and pulmonary vasculature subsequently identified in clinical research — leading to its established application in both erectile dysfunction and pulmonary arterial hypertension treatment protocols referenced in international medical guidelines.
 
⭐ Product Overview
Pharmaceutical-grade sildenafil formulation with consistent 100 mg per tablet concentration and film-coated presentation
The original and most extensively researched PDE5 inhibitor compound in clinical pharmacology literature, with a research history spanning erectile dysfunction, cardiovascular, and pulmonary medicine applications
Established first-line pharmacological intervention for erectile dysfunction management referenced across international urology clinical guidelines
Dual therapeutic application documented in clinical literature — erectile dysfunction and pulmonary arterial hypertension — under the sildenafil designation
Widely referenced in urological, cardiovascular, and pulmonary pharmacology research literature under the sildenafil and Viagra designations worldwide